ArticleASM case reports2026
Management of an infection from NDM-1-producing
Article in ASM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infections with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales are increasingly reported in the United States, with some isolates being reported susceptible to aztreonam (ATM) alone. However, data for the use of ATM as monotherapy are lacking, and current guidelines recommend the use of cefiderocol (FDC) or ceftazidime-avibactam (CZA) plus ATM for severe infections due to concern for co-production of serine beta-lactamases. Case Summary: Here, we report a case of necrotizing soft tissue and surgical hardware infection in an immunocompromised patient with NDM-1-producing Conclusion: This case demonstrates the potential efficacy of ATM therapy, at least for part of the treatment course. Further studies are needed regarding treatment outcomes for ATM-susceptible NDM-producing Enterobacterales infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.